The FDA has approved another biologic treatment, Dupixent, for the treatment of both moderate and severe asthma patients with eosinophilic phenotype
and oral corticosteroid-dependent asthma, regardless of phenotype.
The U.S. Food and Drug Administration today approved Dupixent (dupilumab) to treat adults with nasal polyps (growths on the inner lining of the sinuses) accompanied by chronic rhinosinusitis (prolonged inflammation of the sinuses and nasal cavity). This is the first treatment approved for inadequately controlled chronic rhinosinusis with nasal polyps.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
The U.S. Food and Drug Administration today approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
The U.S. Food and Drug Administration today approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions, including those that are life-threatening (anaphylaxis), in adults and pediatric patients who weigh more than 33 pounds. Teva Pharmaceuticals USA gained approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths.
The U.S. Food and Drug Administration today approved the first generic of Proventil HFA (albuterol sulfate) Metered Dose Inhaler, 90 mcg/Inhalation, for the treatment or prevention of bronchospasm in patients four years of age and older who have reversible obstructive airway disease, as well as the prevention of exercise-induced bronchospasm in this age group.
Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
The U.S. Food and Drug Administration today approved the first generic of ProAir HFA (albuterol sulfate) Inhalation Aerosol for the treatment or prevention of bronchospasm in patients four years of age and older with reversible obstructive airway disease and the prevention of exercise-induced bronchospasm in patients four years of age and older.
FDA's most prominent warning, the Boxed Warning, about asthma-related death has been removed from the drug labels of medicines that contain both an ICS and LABA. A FDA review of four large clinical safety trials shows that treating asthma with long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) does not result in significantly more serious asthma-related side effects than treatment with ICS alone.
[Press Release] FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children Steroid-free SPIRIVA RESPIMAT now approved as asthma treatment for age 6 and older Supplemental New Drug Application (sNDA) approved under priority review from the FDA FDA also granted pediatric exclusivity to SPIRIVA RIDGEFIELD, Conn., Feb. 16, 2017 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and...
AstraZeneca announced that the US Food and Drug Administration (FDA) approved SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol 80/4.5 micrograms for the treatment of asthma in pediatric patients aged six up to 12 years.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
FDA News Release FDA proposes ban on most powdered medical gloves For Immediate Release March 21, 2016 Release Today, the U.S. Food and Drug Administration announced a proposal to ban most powdered gloves in the United States. While use of these gloves is decreasing, they pose an unreasonable and substantial risk of illness or injury to health care providers, patients and other individuals who are exposed to them, which cannot be corrected through new or updated labeling. The proposed ban...
As part of the U.S. Food and Drug Administration’s ongoing efforts to protect consumers from health fraud, the agency is reminding consumers to be wary of unapproved products claiming to prevent, treat or cure influenza, or flu. This year’s severe flu season raises new concerns about the potential for consumers to be lured into buying unproven flu treatments, and even worse, buying counterfeit antivirals online from websites that appear to be legitimate online pharmacies.
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to intranasal corticosteroids.
Welcome to your February advocacy update. I’m Jenna Riemenschneider, director of advocacy at the Asthma and Allergy Foundation of America (AAFA). I am pictured above with AAFA board member Renuka Babu Brown and Senator Ed Markey's (D-MA) policy advisor Adam Axler. Over-the-Counter Drug Access and Cleaner Cars Rollbacks AAFA and other members of the Healthy Choices Coalition met with Representative Judy Chu's office. We asked her to co-sponsor the Restoring Access to Medication Act of 2019...
Shari Duncan has had asthma for more than three decades. In recent years it has become quite severe. Shari takes daily asthma maintenance medicines, does nebulizer breathing treatments and works hard to avoid her biggest asthma triggers. She also uses her quick-relief inhaler about once or twice a week. In spite of these efforts, four to six times a year Shari is hospitalized for asthma.
June is National Healthy Homes Month. Your home can have a big impact on how well you manage your asthma and allergies. Reducing asthma triggers and allergens in your home should be an important part of your asthma and allergy management plan.
Researchers estimate the number of people with food allergies in the U.S. to be 32 million. It breaks down to 6 million children and 26 million adults – more than previously thought. 1 It is common for food allergies to develop in childhood, but you can develop a food allergy at any age. Adults are more likely to develop allergies to crustacean shellfish (like crabs, lobster or shrimp), peanuts, milk, tree nuts and fin fish. 1 Adult-onset food allergies are generally life-long and are not...
The Asthma and Allergy Foundation of America (AAFA) and Rashad Jennings of the New York Giants today announced the launch of their #TackleAsthma campaign to educate and inspire children with asthma. As part of National Asthma and Allergy Awareness Month this May, AAFA and Jennings are working to help families understand and manage the daily challenges of living with asthma.
Note: As of May 16, 2017, GlaxoSmithKline expanded their recall. Additional lot numbers have been added below.
GlaxoSmithKline (GSK) issued a voluntary Class II recall on April 4, 2017 for three lots of Ventolin® HFA 200D Inhalers from U.S. hospitals, pharmacies, retailers and wholesalers as a precautionary measure. It is not a consumer recall.
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data demonstrating that severe asthma patients, whose disease is driven by eosinophilic inflammation, treated with first-in-class biologic Nucala® (mepolizumab) added-on to standard of care, achieved clinically and statistically significant improvements in their health-related quality of life and lung function, when compared to patients treated with placebo and standard of care. These results are from the phase IIIb MUSCA study (NCT02281318, 200
New research shows that climate change is already a significant public health issue and a looming global health emergency. Its findings, outlined in The Lancet medical journal, demonstrate the various ways climate change is already affecting the health of people across the planet, today.
Circassia Pharmaceuticals, Inc. (“Circassia” or “the Company”), a specialty pharmaceutical company focused on respiratory disease, today announced that Fractional Exhaled Nitric Oxide (FeNO) monitoring is recommended in the latest Global Initiative for Asthma (GINA) guide, “Difficult-to-Treat & Severe Asthma in Adolescent and Adult Patients – Diagnosis and Management.”
The Asthma and Allergy Foundation of America (AAFA) joined Moms Clean Air Force on July 11, 2018, to raise awareness about the health impacts of climate change. The Play-In for Climate Action was held on the National Mall. Hundreds of parents and their children from across the U.S. participated in the event to draw attention to the harmful effects of air pollution . Studies show that air pollution can worsen asthma symptoms. Climate change also creates longer and heavier pollen seasons. A...
The Asthma and Allergy Foundation of America is sharing this press release from GlaxoSmithKline to bring you the latest research news quickly. [PRESS RELEASE] GSK announces availability of Authorized Generic Albuterol Sulfate Inhaler for treatment or prevention of bronchospasm Effective, January 15, 2019, GSK announced the availability of an authorized generic (AG) of Ventolin HFA (albuterol sulfate) inhalation aerosol. The AG will be manufactured by GSK and distributed by Prasco LLC. The...
Before you update your flooring, you should know the pros and cons of the two most common options – hardwood and carpet. Style preference is one thing, but which is best for the health of your family? Which one do you think is more asthma and allergy friendly? It's important to learn the advantages and disadvantages of both when shopping for new flooring when you have asthma and allergies. It is important to stay up-to-date on ways to make your home asthma and allergy friendly . By joining...
The Trump Administration released a final rule expanding the scope and applicability of association health plans (AHPs). The Department of Labor’s rule implements President Trump’s October 2017 executive order which directed agencies to change existing regulations to provide consumers with more options for health care coverage.
The Asthma and Allergy Foundation of America (AAFA) hosted a webinar on Thursday, March 30, 2017, about Health Insurance 101 for People with Asthma and Allergies. Watch video on YouTube Our guest speaker was Prue Fitzpatrick, MPH, a member of the Board of Directors for AAFA. She has a background in health care policy, having been involved with recent health reform policy development and implementation, as well as experience working within the insurance industry. Ms. Fitzpatrick discussed:...
This is the time of year when you start hearing a lot about health insurance enrollment for 2017. Here is a review of what you need to know in order to buy a plan, whether you are buying insurance for the first time or switching plans.
If you have asthma or allergies, it is important to have health insurance. Medicines, lab tests, lung function tests and visits to see a specialist all add up. What do you need to know about your insurance options during open enrollment this year?
Many consider personalized medicine the future of health care, and for good reason. As we learn about patients, genetics and diseases, we see that a standard approach is not the best. The purpose of personalized medicine is to provide custom treatment plans for patients. While customized care can help patients, it also adds challenges due to many factors that influence asthma.
Asthma can be scary and overwhelming. It is the leading chronic disease in children and the top reason for missed school days due to chronic illness. I’m sure if you’ve been touched by this disease, you might empathize with this experience from LaJoy and her daughter, Abria.
To mark World Asthma Day, Representatives Eliot L. Engel (NY-16) and Fred Upton (MI-6) have introduced a bipartisan House Resolution designating the month of May as “National Asthma and Allergy Awareness Month.”
It should come as no surprise that the quality of the air we breathe affects our lungs. According to several studies, air pollution can make asthma symptoms worse. It’s also linked to higher asthma-related emergency room visits among senior adults and higher asthma rates in children.
Long, hot days are great for outdoor activities, but pollen can threaten to keep you indoors if you have pollen allergies and allergic asthma. They may leave you longing for a rain shower to wash the pollen away. But rain causes plant growth, producing more pollen, right? So is rain good for those with allergies or not?
The Asthma and Allergy Foundation of America is sharing tips about asthma and allergies on cable television! Watch our first tip April 13 on Access Health airing on Lifetime Television®. We'll share dangers that can trigger an asthma attack . The show airs at 7:30 am ET/PT. This tip will be rebroadcast on April 20. Stay tuned for other tip topics, dates and previews! See the first preview here or watch the video below:
The air we breathe is one of the greatest threats to our respiratory health. Millions of people worldwide die prematurely each year from air pollution. Air pollution affects children the most. Evidence links air pollution to preterm births, underdeveloped lungs, reduced lung function and asthma. In the U.S., of the 25 million who have asthma, 10 die every day.
The Asthma and Allergy Foundation of America (AAFA) believes your voice is valuable part of asthma research. And we want to empower people with asthma, caregivers and health care providers to take an active role in research.
Promoting Asthma Patient Engagement in Research (PAPER) is a new research project from AAFA and the Patient-Centered Outcomes Research Institute (PCORI). Through this project, you can influence research that improves asthma understanding and treatment.
A U.S. Housing and Urban Development (HUD) ban on smoking in public housing starts July 31, 2018. According to the rule, no one can smoke inside public housing. They also cannot smoke within 25 feet of any public housing building.
With the current spread of the new coronavirus (COVID-19) in the U.S. and around the world, many people with asthma wonder how it would affect them if they got the illness. There is a lot we still don't know about this illness. Dr. Mitchell Grayson, the chair of the Asthma and Allergy Foundation of America's (AAFA) Medical Scientific Council, wrote this article for our blog about what we do know at this time. There have been many questions about how having asthma affects your risk of getting...
Health risks from pneumonia are potentially more dangerous than those related to the flu, but large segments of the population aren't being vaccinated against it — even those at highest risk of contracting the disease. They include infants, the elderly and those with chronic respiratory problems like asthma. Streptococcus pneumoniae (“pneumococcus”) is the bacterium responsible for almost a million cases and more than 50,000 deaths from pneumonia every year — twice as many as the number of...
We know that children with pollen food allergy syndrome (PFAS) also suffer from seasonal allergies. A new study being presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Houston shows that allergy shots (subcutaneous immunotherapy) can be effective in reducing PFAS symptoms for pediatric patients.
Press Release Contact: Melissa Graham email@example.com (414) 272-6071 Onsite Press Room (March 4-7): (213) 743-6242 POVERTY WIDENS GAP IN CARE FOR ASTHMA AND ALLERGIES Researchers Examine Socioeconomic Disparities at AAAAI Annual Meeting Los Angeles, CA – Socioeconomic disparities are a cause for concern in patients with asthma and allergies, according to several studies presented at the AAAAI Annual Meeting. “We found that patients who have asthma and come from lower income households –...
When you block a person, they can no longer invite you to a private message or post to your profile wall. Replies and comments they make will be collapsed/hidden by default. Finally, you'll never receive email notifications about content they create or likes they designate for your content.
Note: if you proceed, you will no longer be following .